

Robert G Price

List of Publications by Citations

Source: <https://exaly.com/author-pdf/678646/robert-g-price-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

15 papers	560 citations	9 h-index	18 g-index
18 ext. papers	757 ext. citations	5.1 avg, IF	3.81 L-index

#	Paper	IF	Citations
15	Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study. <i>Clinical Therapeutics</i> , 2016 , 38, 2058-2070.e1	3.5	170
14	Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 143, 1742-1751.e7	11.5	136
13	The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019 , 74, 1716-1726	9.3	57
12	Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study. <i>Clinical Therapeutics</i> , 2019 , 41, 2041-2056.e5	3.5	51
11	Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 144, 1336-1342.e7	11.5	38
10	Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma. <i>Pediatric Pulmonology</i> , 2019 , 54, 1957-1967	3.5	32
9	Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis. <i>Respiratory Research</i> , 2019 , 20, 83	7.3	25
8	Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial. <i>Allergy, Asthma and Clinical Immunology</i> , 2019 , 15, 37	3.2	18
7	Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. <i>Journal of Allergy and Clinical Immunology</i> , 2017 , 140, 1464-1466.e4	11.5	13
6	Stopping continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). <i>European Respiratory Journal</i> , 2021 ,	13.6	8
5	Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics. <i>Respiratory Research</i> , 2021 , 22, 144	7.3	7
4	Assessing efficacy in important subgroups in confirmatory trials: An example using Bayesian dynamic borrowing. <i>Pharmaceutical Statistics</i> , 2021 , 20, 551-562	1	3
3	Mepolizumab for severe eosinophilic asthma: a comparison of efficacy in children, adolescents, and adults 2018 ,		2
2	Prospective Italian real-world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports. <i>Clinical and Translational Allergy</i> , 2021 , 11, e12067	5.2	0
1	Development of methodology for assessing steroid-tapering in clinical trials for biologics in asthma.. <i>Respiratory Research</i> , 2022 , 23, 45	7.3	0